(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
-1.96% $ 5.99
Live Chart Being Loaded With Signals
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system...
Stats | |
---|---|
Volumen de hoy | 47 530.00 |
Volumen promedio | 147 690 |
Capitalización de mercado | 254.97M |
EPS | $0 ( 2024-03-14 ) |
Próxima fecha de ganancias | ( $-0.550 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.56 |
ATR14 | $0.0800 (1.34%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Humer Kristian | Buy | 275 000 | Stock Option (Right to buy) |
2024-04-16 | Humer Kristian | Buy | 0 | |
2024-03-11 | Cavalie Fanny | Sell | 11 000 | Common Stock |
2024-01-24 | Gottschalk Adrian | Buy | 300 000 | Stock Option (right to buy) |
2024-01-24 | Cardama Alfonso Quintas | Buy | 60 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
43.24 |
Last 90 transactions |
Buy: 4 432 955 | Sell: 2 595 211 |
Volumen Correlación
Foghorn Therapeutics Inc. Correlación
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Foghorn Therapeutics Inc. Correlación - Moneda/Commodity
Foghorn Therapeutics Inc. Finanzas
Annual | 2023 |
Ingresos: | $34.16M |
Beneficio Bruto: | $25.49M (74.64 %) |
EPS: | $-2.34 |
FY | 2023 |
Ingresos: | $34.16M |
Beneficio Bruto: | $25.49M (74.64 %) |
EPS: | $-2.34 |
FY | 2022 |
Ingresos: | $19.23M |
Beneficio Bruto: | $19.21M (99.90 %) |
EPS: | $-2.62 |
FY | 2021 |
Ingresos: | $1 319.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.00274 |
Financial Reports:
No articles found.
Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico